Hypoxia and Hypoxic Conditions
Hypoxia, or lack of oxygen to tissue, is a common underlying factor in morbidity and mortality for numerous serious medical conditions. There is a substantial unmet need for a pharmacological treatment for hypoxia.
- When deprived of oxygen, normal cells quickly begin to die; cancerous cells become resistant to radiation and chemotherapy
- Severe hypoxia in normal cells results in loss of consciousness, tissue necrosis, neurological incapacitation, or death
- Acute hypoxia occurs with hemorrhage or when the flow of oxygenated blood to a local region is restricted by trauma, an embolus such as a blood clot, or atherosclerosis, such as peripheral arterial disease or stroke
- Tumor hypoxia occurs when the growth of cancerous tumor cells outpaces oxygen supply
The potential clinical applications for a novel therapy that addresses hypoxia are significant.
- Oncology: Radiosensitizer to enhance radiation response for cancerous tumors
- Critical/Acute Care: Stroke, heart attack, trauma, hemorrhage
- Chronic Care: Cardiovascular disease, respiratory disorders, peripheral arterial disease
Potential Indications for TSC
A novel treatment for hypoxic conditions, such as TSC, could have wide clinical application. The Company’s strategic focus is on its use to improve the response of cancerous tumors to radiation and chemotherapy.
|
Treatment of Cancerous Tumors in Conjunction with Radiation Therapy
|
Peripheral Arterial Disease (PAD)
|
Stroke, Cardiovascular, and Respiratory Disease
|
Trauma and Hemorrhagic Shock
|
|
| Background | Cancerous tumors often grow faster than their ability to form new blood vessels, leading to hypoxic cells.The non-responsiveness of cancerous tumors to radiation therapy is linked to oxygen deficiency within the cells of the tumor. | Peripheral Arterial Disease (PAD) refers to the narrowing of blood vessels outside of the heart and brain.This often occurs when fatty deposits build up in the inner lining of artery walls.The American Heart Association estimates that PAD affects up to 12 million Americans. | Ischemic conditions caused by stroke, myocardial infarction or respiratory disease:–Strokes affect 600,000 to 750,000 Americans each year–Cardiovascular disease affects ~22 million Americans and is the leading cause of death in the U.S.
–Respiratory disease covers a wide range of conditions, ranging from asthma to emphysema |
Hemorrhagic shock occurs when blood loss exceeds the body’s ability to compensate and provide adequate tissue oxygenation.Death due to blood loss is the major cause of death on the battlefield. |
| Opportunity | Preclinical data show TSC improves oxygenation of the tumor, increasing the effectiveness of radiation therapy, thus increasing survival. | TSC may improve oxygenation of muscle tissue and relieve the pain of peripheral arterial disease in both acute and chronic situations. | Pre-clinical data indicate TSC improves oxygenation in each of these conditions. | Preclinical data show TSC acts as a resuscitation agent in severe blood loss or other trauma, improving oxygenation and preventing tissue damage, increasing survival. |
